Dermatology Calculators

Lund-Browder / Rule of Nines method for estimating total body surface area burned. Guides fluid resuscitation and transfer criteria.

Standard severity scoring for plaque psoriasis. PASI ≥10 typically indicates moderate-to-severe disease requiring systemic treatment.

10-item patient-reported outcome measure for quality of life in skin conditions. Combined with PASI to assess biologic eligibility.

ABCDE checklist for clinical evaluation of suspicious pigmented lesions. Positive features prompt urgent dermatology referral.

Validated severity score for atopic dermatitis (eczema) used to assess treatment response and biologic eligibility.

Severity-of-illness score for toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) to predict mortality.

Breslow thickness is the primary determinant of melanoma T-stage and sentinel lymph node biopsy eligibility. Based on AJCC 8th edition staging.

7-day urticaria activity score assessing wheals and pruritus, used to guide antihistamine dosing and omalizumab eligibility in chronic spontaneous urticaria (CSU).

4-item clinical scar assessment tool evaluating vascularity, pigmentation, pliability, and height. Total score 0–13; higher score = worse scar. Used to assess burn scars, surgical scars, and response to treatment (silicone gel, pressure garments, laser therapy).

Stages cutaneous melanoma based on Breslow thickness, ulceration, and mitotic rate per AJCC 8th edition. Guides surgical margin and sentinel lymph node biopsy decisions.

Quantifies psoriasis severity by assessing extent and intensity across four body regions. PASI >=10 defines moderate-severe psoriasis eligible for systemic therapy.

Patient-reported quality of life questionnaire for skin disease. DLQI >10 indicates very large impact; combined with PASI triggers biologic eligibility.

Quantifies atopic dermatitis severity across four body regions. EASI >=16 = severe eczema; guides systemic/biologic therapy eligibility (dupilumab).

Diagnoses Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) using RegiSCAR criteria. Score >=4 indicates definite DRESS.

Classifies acne vulgaris severity using the Investigator Global Assessment (IGA) scale. Guides topical vs systemic vs isotretinoin prescribing.

Assesses disease activity in vitiligo using the Vitiligo Disease Activity (VIDA) score. Guides treatment selection (immunosuppression vs phototherapy vs surgical).

Age-adjusted body-surface chart for estimating second- and third-degree burn TBSA. More accurate than Rule of Nines, particularly in children where the head accounts for a disproportionately large surface area. Use the resulting TBSA% with the Parkland formula for fluid resuscitation.

European Task Force on Atopic Dermatitis severity index. Total = A/5 + 7B/2 + C, where A = extent (0–100% TBSA), B = sum of 6 intensity items (each 0–3, max 18), C = subjective pruritus + sleep loss VAS (0–20). Pick severity band below — or compute the formula manually.

7-item patient/parent-reported atopic eczema symptom score (Charman 2004). Each item 0–4 (days in past week). Total 0–28. Recommended core outcome by HOME initiative.

Three-stage clinical classification of hidradenitis suppurativa (Hurley 1989). Drives initial therapeutic stratification per BAD 2018 guidelines.

Quantitative dynamic activity score for HS (Sartorius 2003, modified 2009). Sums points by anatomical region, lesion type and distance between lesions. Use the band closest to your calculated value.

Standard quantitative melasma severity score (Kimbrough-Green 1994, modified Pandya 2011). Total 0–48 (0–24 for mMASI). Used in clinical trials and PROM monitoring.